Introduction
The occurrence of post-gastrectomy bone disorders has been explained in terms of impaired calcium (Ca) absorption, reduced milk intake, and decreased food intake [1] . As is done for patients with ordinary osteoporosis, Ca and vitamin supplements are administered to treat patients with post-gastrectomy bone disorders [2, 3] . As drugs that inhibit bone resorption by osteoclasts have also been developed recently [4, 5] , a variety of treatment options is now available to manage bone disorders arising after gastrectomy for gastric cancer. It has been reported that the serum level of 25(OH) vitamin D3 is decreased and the serum level of 1,25(OH) 2 vitamin D3 is increased in gastrectomy patients [6] . However, to the best of our knowledge, there have been no reports about changes in vitamin D3 (VD) metabolites. We previously reported that the administration of 1α hydroxy vitamin D3 (1α) was effective for treating post-gastrectomy bone disorders [7] . However, it has also been reported that the administration of such VD preparations has an adverse infl uence on bone metabolism [8] . Against this background, we performed the present study to obtain evidence to support the administration of 1α for treating post-gastrectomy bone disorders.
Patients and methods
The study involved 22 outpatients who had undergone gastrectomy for gastric cancer and had not been treated with 1α or Ca, and who gave informed consent for blood sampling for biochemistry tests. They comprised 17 men and 5 women, with a mean age of 61.9 years (range, Abstract Background. We previously reported that the administration of 1a hydroxy vitamin D3 was effective for treating postgastrectomy bone disorders. Accordingly, we performed the present study to obtain evidence supporting the effectiveness of 1a hydroxy vitamin D3 in post-gastrectomy patients. Methods. The study involved 22 outpatients who had undergone gastrectomy for gastric cancer and had not been treated with 1a hydroxy vitamin D3 or calcium. They comprised 17 men and 5 women, with a mean age of 61.9 years. Laboratory tests were performed to examine the following parameters: 1,25(OH) 2 35-85 years). Four patients had been treated by total gastrectomy, 13 had undergone subtotal Billroth-I gastrectomy, and 5 had received subtotal Billroth-II gastrectomy. The postoperative period until the beginning of the study ranged from 2 months to 14 years ( Table  1) . Because of the VD pathway, we performed laboratory tests to examine the following parameters: 1,25(OH) 2 VD (normal range, 20-76 ng/ml); 25(OH)VD (normal range, 10-55 ng/ml); 24,25(OH) 2 VD (normal range, 1.8-3.8 ng/ml); ionized Ca (normal range, 2.21-2.52 mEq/l); Ca (normal range, 4.25-4.90 mEq/l); phosphorus (P; normal range, 1.45-2.49 mEq/l); alkaline phosphatase (ALP; normal range, 79-224 mU/ ml); N-parathyroid hormone (N-PTH; normal range, 230-630 pg/ml); and osteocalcin (normal range, 1.5-6.5 ng/ml).
Statistical analyses were performed using the χ 2 test, Student's t-test, and multivariate analysis. Statistical signifi cance was defi ned as P < 0.05.
Results
The level of 1,25(OH) 2 VD, the most active of the VD metabolites, was found to be normal in all of the patients. That is, serum 1,25(OH) 2 VD did not decrease over time after gastrectomy and was not affected by the type of gastrectomy procedure. In contrast, the level of 25(OH)VD, which shows weak activity, was below the normal range in 7 of the 22 patients (32%). One of the 6 patients (17%) tested at less than 1 year postoperatively had a 25(OH)VD below the normal range, versus 6 of the 16 patients (38%) tested at 1 year or more postoperatively, although the difference between the two groups was not statistically signifi cant (Fig. 1) . However, the mean serum level of 25(OH)VD was signifi cantly lower in patients at 1 year or more postoperatively than in those at less than 1 year postoperatively (P = 0.041), as well as being signifi cantly lower in patients (Fig. 1) . The mean 24,25(OH) 2 VD level was lower, although not signifi cantly so, in patients at 1 year or more postoperatively than in patients at less than 1 year postoperatively, as was the case for 25(OH)VD. The mean 24,25(OH) 2 VD level was also lower, although not signifi cantly so, in patients who had received a total gastrectomy (Table  2) . From a comparison of these three VD metabolites, the following results were obtained: the 1,25(OH) 2 VD/ 25(OH)VD ratio was signifi cantly higher after a total gastrectomy, after gastrectomy procedures avoiding the duodenal passage of food, and at 1 year or more postoperatively, while the 25(OH)VD/24,25(OH) 2 VD ratio was signifi cantly lower after gastrectomy procedures avoiding the duodenal passage of food ( Table 2) .
The ionized Ca level was above the normal range in 9 of the 22 patients (41%), and was not below the normal range in any of the patients. Calcium was below the normal range in 1 of the 22 patients (5%). Phosphorus was also below the normal range in 1 of the 22 patients (5%). The ALP level was above the normal range in 12 of the 22 patients (55%). N-PTH was above the normal range in 1 of the 22 patients (5%), but was below the normal range in 11 patients (50%; Fig 2) .
The levels of ionized Ca, Ca, P, ALP, and N-PTH did not differ in relation to the postoperative period or the type of gastrectomy procedure. The osteocalcin level was above the normal range in all of the patients.
On multivariate analyses, factors associated with the change in VD metabolites did not remain (Table 3) . , and osteocalcin in gastrectomy patients. The serum level of ionized calcium was higher than the normal range in 9/22 patients (41%), and was not lower than the normal range in any of the patients. The serum calcium level was lower than the normal range in 1/22 patients (5%), and the serum phosphorus level was also lower than the normal range in 1/22 patients (5%). The serum ALP level was higher than the normal range in 12/22 patients (55%). The serum N-PTH level was higher than the normal range in 1/22 patients (5%), while it was lower than the normal range in 11/22 patients (50%). The serum osteocalcin level was higher than the normal range in all of the patients. White dotted bars, low level; striped bars, normal level; black bars, high level
Discussion
An extensive number of reports have been published regarding the postoperative complications of gastrectomy for gastric cancer, including the dumping syndrome. Vitamin B12 malabsorption and bone disorders are also widely known post-gastrectomy complications [9] , but intensive studies have not been performed and there are few reports with respect to changes in serum VD levels after gastrectomy. A number of investigators have reported that gastrectomy for gastric cancer leads to changes in bone metabolism and an increased risk of fracture [10] [11] [12] [13] [14] . We studied changes in circulating VD metabolites in patients who had undergone a gastrectomy for gastric cancer. Although a change in VD metabolism was observed, the increase in PTH that has been reported by other authors was not seen [6] . This suggests that post-gastrectomy bone disorders may progress slowly without an increase in PTH, unlike the fi ndings in hyperparathyroidism. Figure 3 shows the formation and hydroxylation of VD [15] . The formation of 25(OH)VD takes place in the liver, and the formation of 1,25(OH) 2 VD occurs in the kidneys. In gastrectomized patients, food intake is reduced and malabsorption of fat occurs, and the formation of 25(OH)VD is reduced in the liver. However, the formation of 1,25(OH) 2 VD in the kidneys does not decrease to maintain the serum Ca level. In the present study, many patients showed a decrease in 25(OH)VD and 24,25(OH) 2 VD, which are metabolites that show weak activity. This suggests that a homeostatic response maintains the normal level of 1,25(OH) 2 VD, which is important in the regulation of Ca. Figure 4 shows the current understanding of Ca and bone metabolism after gastrectomy, according to the literature and our data. We guess that, because of the normal 1,25(OH) 2 D level in our patients, the pathway of 25(OH)D to 24,25(OH) 2 D was not stimulated and therefore PTH did not increase. However, in spite of the normal levels of 1,25(OH) 2 D, the formation of 1,25(OH) 2 D was stimulated. Because of the gastrec- Thus, our fi ndings suggested that gastrectomy had a moderate infl uence on the metabolism of VD. It was previously reported that no therapeutic response was obtained with Ca or VD supplements in postgastrectomy osteoporosis. [8] Nevertheless, it is reasonable to expect that bone metabolism could be improved by rectifying the changes in VD metabolism. Zittel et al. [6 ] reported that the serum Ca level was decreased, while the serum levels of Ca-regulating PTH and 1,25(OH) 2 VD were increased, in patients who had had a total gastrectomy compared with control subjects, and these changes were more prominent after a total gastrectomy than after subtotal gastrectomy. This is a different outcome to the result of our study, and may indicate the necessity for taking ethnic differences into consideration. However, our results showing a high 1,25(OH) 2 VD/ 25(OH)VD ratio after a total gastrectomy, after gastrectomy procedures avoiding duodenal passage of food, and at 1 year or more postoperatively may indicate a high risk of bone fracture, as noted in the report of Zittel et al. [6 ] .
There have been various reports regarding post-gastrectomy changes in Ca regulation. It was reported that the decrease in the serum Ca level was similar in patients with subtotal gastrectomy and those with total gastrectomy [13, 14] . However, our patients showed virtually no decrease in serum Ca and maintained a serum ionized Ca level that was above the normal range. Free ionized Ca has an important role as a messenger in the blood coagulation response, muscle contraction, and nerve function [15] , so our fi ndings suggest that the amount of ionized Ca in gastrectomy patients is adequate to maintain normal biological functions.
In regard to the proportions of the three VD metabolites, a marked decrease in 25(OH)VD was found after a total gastrectomy and after procedures that allowed food to bypass the duodenum. This suggests that VD absorption may be severely disturbed in patients who undergo total gastrectomy or the Roux-en-Y reconstruction to treat gastric cancer.
Few reports are available regarding changes in the levels of other vitamins, such as lipid-soluble vitamin A, vitamin E, and vitamin K after gastrectomy. However, it has been reported that the serum levels of vitamins A and E are decreased by a total gastrectomy [16, 17] , and there is a report suggesting that vitamin K may also be decreased in patients who have had a total gastrectomy [16] .
The administration of 1α results in activation of the metabolic pathway from 25(OH)VD to 24,25(OH) 2 VD and obviates the need for compensatory changes in VD metabolism that are needed to maintain a normal 1,25(OH) 2 VD level, such as the enhancement of the metabolic pathway from 25(OH)VD to 1,25(OH) 2 VD or the suppression of the pathway from 25(OH)VD to 24,25(OH) 2 VD. Thus, normal VD metabolism can be restored by the use of 1α.
Conclusion
Bone disorders following gastrectomy may occur because Ca and VD absorption are decreased due to a decrease in food intake, rather than because of a loss of hormone balance (including PTH) after gastric resection. Our results suggest that, after gastric resection, some VD metabolites decrease and bone disease devel- Dashed arrow shows that we have no idea how bone turnover is accelerated by the change in VD metabolites, but the accelerated formation of 1,25(OH) 2 D would probably stimulate bone turnover ops gradually, unlike the rapid bone changes caused by hyperparathyroidism. The administration of 1α seems to be effective for the treatment and prevention of bone disorders after gastrectomy for gastric cancer because it improves the balance of VD metabolites. To reach a defi nitive conclusion on this treatment, it will be necessary to examine a greater number of patients receiving 1α and to conduct additional assessments in the future.
